254 related articles for article (PubMed ID: 37582200)
1. The contribution of endothelial cells to tissue fibrosis.
Romano E; Rosa I; Fioretto BS; Manetti M
Curr Opin Rheumatol; 2024 Jan; 36(1):52-60. PubMed ID: 37582200
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis.
Rosa I; Romano E; Fioretto BS; El Aoufy K; Bellando-Randone S; Matucci-Cerinic M; Manetti M
Cells; 2023 Sep; 12(17):. PubMed ID: 37681927
[TBL] [Abstract][Full Text] [Related]
3. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
4. The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting.
Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M
Curr Mol Med; 2022; 22(3):209-239. PubMed ID: 33823766
[TBL] [Abstract][Full Text] [Related]
5. Endothelium-mediated contributions to fibrosis.
Sun X; Nkennor B; Mastikhina O; Soon K; Nunes SS
Semin Cell Dev Biol; 2020 May; 101():78-86. PubMed ID: 31791693
[TBL] [Abstract][Full Text] [Related]
6. Endothelial-to-mesenchymal transition in systemic sclerosis.
Di Benedetto P; Ruscitti P; Berardicurti O; Vomero M; Navarini L; Dolo V; Cipriani P; Giacomelli R
Clin Exp Immunol; 2021 Jul; 205(1):12-27. PubMed ID: 33772754
[TBL] [Abstract][Full Text] [Related]
7. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.
Hinz B; Lagares D
Nat Rev Rheumatol; 2020 Jan; 16(1):11-31. PubMed ID: 31792399
[TBL] [Abstract][Full Text] [Related]
8. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
Korman B
Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
[TBL] [Abstract][Full Text] [Related]
9. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N
Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320
[TBL] [Abstract][Full Text] [Related]
10. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?
Karasek MA
Med Hypotheses; 2007; 68(3):650-5. PubMed ID: 17045756
[TBL] [Abstract][Full Text] [Related]
11. New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.
Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M
Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34202703
[TBL] [Abstract][Full Text] [Related]
12. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.
Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786
[TBL] [Abstract][Full Text] [Related]
13. Reduced SPAG17 Expression in Systemic Sclerosis Triggers Myofibroblast Transition and Drives Fibrosis.
Sapao P; Roberson EDO; Shi B; Assassi S; Skaug B; Lee F; Naba A; Perez White BE; Córdova-Fletes C; Tsou PS; Sawalha AH; Gudjonsson JE; Ma F; Verma P; Bhattacharyya D; Carns M; Strauss JF; Sicard D; Tschumperlin DJ; Champer MI; Campagnola PJ; Teves ME; Varga J
J Invest Dermatol; 2023 Feb; 143(2):284-293. PubMed ID: 36116512
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic factors as drivers of fibrosis in systemic sclerosis.
Bergmann C; Distler JH
Epigenomics; 2017 Apr; 9(4):463-477. PubMed ID: 28343418
[TBL] [Abstract][Full Text] [Related]
15. The Vessels Contribute to Fibrosis in Systemic Sclerosis.
Di Benedetto P; Ruscitti P; Liakouli V; Cipriani P; Giacomelli R
Isr Med Assoc J; 2019 Jul; 21(7):471-474. PubMed ID: 31507123
[TBL] [Abstract][Full Text] [Related]
16. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis.
Beon M; Harley RA; Wessels A; Silver RM; Ludwicka-Bradley A
Clin Exp Rheumatol; 2004; 22(6):733-42. PubMed ID: 15638048
[TBL] [Abstract][Full Text] [Related]
17. Interfacial Adipose Tissue in Systemic Sclerosis.
Kruglikov IL
Curr Rheumatol Rep; 2017 Jan; 19(1):4. PubMed ID: 28138823
[TBL] [Abstract][Full Text] [Related]
18. CXCL4 drives fibrosis by promoting several key cellular and molecular processes.
Affandi AJ; Carvalheiro T; Ottria A; de Haan JJ; Brans MAD; Brandt MM; Tieland RG; Lopes AP; Fernández BM; Bekker CPJ; van der Linden M; Zimmermann M; Giovannone B; Wichers CGK; Garcia S; de Kok M; Stifano G; Xu YJ; Kowalska MA; Waasdorp M; Cheng C; Gibbs S; de Jager SCA; van Roon JAG; Radstake TRDJ; Marut W
Cell Rep; 2022 Jan; 38(1):110189. PubMed ID: 34986347
[TBL] [Abstract][Full Text] [Related]
19. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease.
He J; Xu Y; Koya D; Kanasaki K
Clin Exp Nephrol; 2013 Aug; 17(4):488-97. PubMed ID: 23430391
[TBL] [Abstract][Full Text] [Related]
20. TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis.
Dees C; Pötter S; Zhang Y; Bergmann C; Zhou X; Luber M; Wohlfahrt T; Karouzakis E; Ramming A; Gelse K; Yoshimura A; Jaenisch R; Distler O; Schett G; Distler JH
J Clin Invest; 2020 May; 130(5):2347-2363. PubMed ID: 31990678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
